TUESDAY, JUNE 19, 2018

Study finds PCV effective as pneumonia treatment

A recent study discovered that a 10-valent pneumococcal conjugate vaccine (PCV) was effective in reducing community-acquired pneumonia in infants.

The results of the study, published in PLOS Medicine by Panama's Department of Infectious Diseases, found that the 10-valent PCV reduced the amount of new cases of community-acquired pneumonia by 22 percent in infants in Latin America versus those who received a control vaccine.

The study included a double-blind randomized controlled trial that tested 23,821 infants in urban areas of Argentina, Panama and Colombia. Half of the infants received a 10-valent PCV at two, four and six months of age, with a booster shot at 15-18 months. The other half received a hepatitis control vaccine during the same intervals.

At the end of the study, 18.2 percent less cases of pneumonia were reported in the first group than the control group. Serious adverse affects were reported in approximately 20 percent of the children, though there were similar numbers of reports in both the PCV and control groups, indicating PCV was not the cause.

"Now, children of Latin America and elsewhere in the world can benefit from a vaccine that has demonstrated efficacy against a variety of pneumococcal infections associated with substantial morbidity and mortality," the authors of the study said.